- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03512210
Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection (MINMON)
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study evaluated the feasibility, safety, and efficacy of a minimal monitoring (MINMON) strategy of delivering interferon- and ribavirin (RBV)-free, pan-genotypic direct-acting antiviral (DAA) therapy to treat active hepatitis C virus (HCV) in HCV treatment naïve participants, with or without HIV-1 co-infection, and with no evidence of decompensated cirrhosis.
The MINMON intervention included four components: 1) No pre-treatment HCV genotyping; 2) Entire 12-week treatment course (84 tablets) dispensed to participants at study entry; 3) No scheduled on-treatment laboratory monitoring or clinic visits prior to SVR evaluation scheduled 24 weeks following entry; 4) Remote contact with participants at week 4 for adherence counseling and locator update, and week 22 for scheduling of SVR visit and locator update.
At study entry, all participants received a single-tablet, fixed-dose combination (FDC) of sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks.
The trial was designed to accrue 400 adult participants who may be co-infected with HIV-1 (limited to no more than 200 participants), and whose liver disease state is either no cirrhosis (defined by Fibrosis-4 score) or compensated cirrhosis (defined by Fibrosis-4 and Child-Turcotte-Pugh (CTP) scores, and limited to no more than 80 participants). Accrual from research sites in the United States was limited to no more than 132 participants.
The study proceeded in two steps: Step 1: MINMON intervention and Step 2: post-MINMON follow up.
During Step 1 (MINMON intervention), participants were contacted remotely at week 4 to inquire about study medication adherence and confirm locator information, and again at week 22 to schedule the sustained virologic response (SVR) evaluation and confirm locator information. Unplanned in-person clinic visits before week 22 were permissible to address common treatment toxicities that could not be managed remotely. The primary efficacy outcome measure, sustained virologic response (SVR), was evaluated starting at the week 24 study visit. Early discontinuation of treatment did not alter the timing of the SVR evaluation. If the week 24 visit was missed, SVR could be evaluated at any time up to 76 weeks following study entry.
Following SVR evaluation, participants entered Step 2 for two additional post-SVR evaluation study visits at weeks 48 and 72. Participants were contacted remotely at weeks 42 and 68 to schedule such visits. The schedule of additional post-MINMON evaluation visits were dependent on the week of Step 2 entry.
In version 1 of the study, total study duration was up to 76 weeks. Due to the COVID-19 Pandemic, the window of the week 72 visit was extended for participants who completed SVR evaluations and registered to Step 2 to October 31, 2020 for US sites and to February 28, 2021 for non-US sites. This extension did not alter the window for SVR evaluation.
All scheduled in-clinic study visits included a physical exam, blood collection, and collection of plasma samples. For participants able to become pregnant, pregnancy testing was conducted at screening, entry, and at any in-clinic visit during Step 1 if pregnancy was suspected. Liver Elastography was an optional evaluation.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Rio de Janeiro, Brazil, 21045
- Instituto de Pesquisa Clinica Evandro Chagas (12101)
-
-
RS
-
Porto Alegre, RS, Brazil, 9043010
- Hospital Nossa Senhora da Conceicao CRS (12201)
-
-
-
-
-
San Juan, Puerto Rico, 00931
- Puerto Rico-AIDS CRS (5401)
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa, 2193
- University of the Witwatersrand Helen Joseph (WITS HJH) CRS (11101)
-
-
West Cape
-
Cape Town, West Cape, South Africa, 7505
- Family Clinical Research Unit (FAM-CUR) CRS (8950)
-
-
-
-
-
Chiang Mai, Thailand, 50200
- Chiang Mai University HIV Treatment CRS (31784)
-
-
Patumwan
-
Bangkok, Patumwan, Thailand, 10330
- Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (31802)
-
-
-
-
-
Kampala, Uganda
- Joint Clinical Research Centre (JCRC) (12401)
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Alabama CRS (31788)
-
-
California
-
Los Angeles, California, United States, 90033-1079
- University of Southern California (1201)
-
Los Angeles, California, United States, 90095
- UCLA CARE Center CRS (601)
-
San Diego, California, United States, 92103
- Ucsd, Avrc Crs (701)
-
San Francisco, California, United States, 94110
- Ucsf Aids Crs (801)
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Hospital CRS (6101)
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20009
- Whitman Walker Health CRS (31791)
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- The Ponce de Leon Center CRS (5802)
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University CRS (2701)
-
Chicago, Illinois, United States, 60612
- Rush Univ. Med. Ctr. ACTG CRS (2702)
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins University CRS (201)
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hosp. ACTG CRS (107)
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital (MGH) CRS (101)
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington U CRS (2101)
-
-
New Jersey
-
Newark, New Jersey, United States, 07103
- New Jersey Medical School Clinical Research Center CRS (31786)
-
-
New York
-
New York, New York, United States, 10032
- Columbia Physicians and Surgeons CRS (30329)
-
New York, New York, United States, 10010
- Weill Cornell Chelsea CRS (7804)
-
New York, New York, United States, 10065
- Weill Cornell Upton CRS (7803)
-
Rochester, New York, United States, 14642
- University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Unc Aids Crs (3201)
-
Greensboro, North Carolina, United States, 27401
- Greensboro CRS (3203)
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Univ. of Cincinnati CRS (2401)
-
Cleveland, Ohio, United States, 44106
- Case CRS (2501)
-
Columbus, Ohio, United States, 43210
- The Ohio State Univ. AIDS CRS (2301)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hosp. of the Univ. of Pennsylvania CRS (6201)
-
Pittsburgh, Pennsylvania, United States, 15213
- Pittsburgh CRS (1001)
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02906
- The Miriam Hospital ACTG CRS (2951)
-
-
Tennessee
-
Nashville, Tennessee, United States, 37204
- Vanderbilt Therapeutics (VT) CRS (3652)
-
-
Texas
-
Dallas, Texas, United States, 75208
- Trinity Health and Wellness Center CRS (31443)
-
Houston, Texas, United States, 77030
- Houston AIDS Research Team CRS (31473)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Active Hepatitis C (HCV) infection, defined by HCV RNA >1000 international units (IU/mL) within 35 days prior to study entry
- HCV treatment naïve
- Liver disease staged as either non-cirrhotic (Fibrosis-4 (FIB-4) Score <3.25) or compensated cirrhotic (FIB-4 Score ≥3.25 and Child-Turcotte-Pugh (CTP) ≤Score 6) within 35 days prior to study entry
- HIV-1 negative, or HIV-1 positive with either a) Non-efavirenz containing antiretroviral therapy (ART) started at least 14 days prior to study entry with plasma HIV-1 RNA <400 copies/mL within 90 days prior to study entry or b) not taking ART and CD4+ cell count >350 cells/uL within 90 days prior to study entry
The following laboratory values obtained within 35 days prior to study entry:
- Albumin >3.0 g/L
- Hemoglobin >8.0 g/dL for women; >9.0 g/dL for men
- Platelet count >50,000/mm^3
- Calculated creatinine clearance (CrCl) >30 mL/min
- Aspartate aminotransferase (AST) <10 times the upper limit of the normal range (ULN)
- Alanine transaminase (ALT) <10 times the ULN
- Total bilirubin <1.5 times the ULN for participants not on atazanavir (ATV); <3 times the ULN for participants on ATV
- International normalized ratio (INR) <1.5 times the ULN
- For females of reproductive potential, a negative serum or urine pregnancy test within 48 hours prior to study entry
- All participants of reproductive potential must have agreed not to participate in conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization) while on study treatment and for 6 weeks after stopping study treatment
- If participating in sexual activity that could lead to pregnancy, the all participants of reproductive potential had to agree to use at least one reliable methods of contraception while on study treatment and for 6 weeks after stopping study treatment
- Participants who were not of reproductive potential were eligible without requiring the use of contraceptives.
- Life expectancy >12 months
- Ability and willingness to be contacted remotely
- Ability and willingness of participant to provide informed consent.
Exclusion Criteria:
- Positive for hepatitis B virus (HBV) surface antigen
- For cirrhotic participants, CTP score >6 corresponding to Class B or C
- Breastfeeding or pregnancy
- Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation
- Active drug or alcohol use or dependence and other conditions that, in the opinion of the site investigator, would interfere with adherence to study requirements.
- Acute or serious illness requiring systemic treatment and/or hospitalization within 35 days prior to study entry
- For HIV positive participants, presence of active or acute AIDS-defining opportunistic infections within 35 days prior to study entry
- Any history of hepatic decompensation including ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, and/or bleeding esophageal varices
- Use of prohibited medications within the past 14 days prior to study entry
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MINMON 24 weeks with SOF/VEL 12 Weeks
Participants received Sofosbuvir/Velpatasvir (SOF/VEL [Tradename: Epclusa®]) tablet for 12 weeks with a minimal monitoring (MINMON) strategy for 24 weeks
|
400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.
Other Names:
MINMON Strategy:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Sustained Virologic Response 12 (SVR12)
Time Frame: From at least 22 weeks and up to 76 weeks from treatment initiation
|
SVR12 was defined as plasma HCV RNA less than the lower limit of quantification (LLOQ) from the earliest sample drawn at least 22 weeks following study treatment initiation (i.e. at a visit scheduled at least 10 weeks after scheduled end of study treatment). Participants without any HCV RNA result at least 22 weeks after treatment initiation will be considered as having HCV RNA greater than the LLOQ. LLOQ was defined as <15 IU/mL for results tested at USA centralized testing laboratory Quest using the "Roche COBAS® HCV Quantitative nucleic acid test for use on the COBAS® 6800/8800" assays for quantitation (and detection) of HCV, and <12 IU/mL for results tested at regional international labs using "Abbott RealTime HCV" assay for quantitation (and detection) of HCV. A two-sided 95%, confidence interval was calculated for this percentage using the Wilson (score) method. |
From at least 22 weeks and up to 76 weeks from treatment initiation
|
Percentage of Participants With an Occurrence of Serious Adverse Events According to International Council for Harmonization (ICH) Criteria
Time Frame: From treatment initiation to 28 weeks
|
Serious adverse events (SAEs) as defined by ICH guidelines. A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method. |
From treatment initiation to 28 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With at Least One Unplanned Clinic Visit Prior to SVR12 Evaluation
Time Frame: From treatment initiation to 22 weeks
|
According to the study minimal monitoring intervention, there were no planned clinic visits prior to study week 24, when SVR12 was scheduled to be evaluated. An unplanned clinic visit was defined as an in-clinic visit occurring from treatment initiation to up to week 22. A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method. |
From treatment initiation to 22 weeks
|
Percentage of Participants With an Occurrence of One or More Non-serious, Grade >= 3 Adverse Event (AE), or Treatment Limiting AE.
Time Frame: From treatment initiation to 28 weeks
|
AEs included all primary diagnoses, primary signs/symptoms, and primary laboratory abnormalities that either had severity grade ≥ 3 or led to a change in study medication. Serious Adverse Events (SAE) by International Council for Harmonization (ICH) criteria were excluded as they contributed to the primary safety outcome measure. Severity grading was based on DAIDS AE Grading Table, Corrected Version 2.1. A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method. |
From treatment initiation to 28 weeks
|
Percentage of Participants Who Prematurely Discontinued HCV Study Medications
Time Frame: From at least 22 weeks and up to 76 weeks from treatment initiation
|
Since there were no planned clinic visits during the 12 week study medication period, the last dose of study treatment was self-reported by participants, and recorded at the SVR evaluation visit at 24 weeks. Premature treatment discontinuation was defined when the self-reported final dose date was <11 weeks (<77 days) after the date of initial dose (accounting for any reported treatment holds). Participants discontinuing study follow up without information about completion of HCV study medications were counted as having prematurely discontinued medications. A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method. |
From at least 22 weeks and up to 76 weeks from treatment initiation
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Sunil Solomon, MBBS, PhD, MPH, Johns Hopkins University
Publications and helpful links
Helpful Links
- Manual for Expedited Reporting of Adverse Events to DAIDS (DAIDS EAE Manual), Version 2.0, January 2010
- DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1
- NIH. BLAST® Basic Local Alignment Search Tool. US National Library of Medicine, National Center for Biotechnology Information, NIH; 2021
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Disease Attributes
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Hepatitis
- Liver Diseases
- Infections
- Communicable Diseases
- Hepatitis C
- Anti-Infective Agents
- Antiviral Agents
- Sofosbuvir
- Sofosbuvir-velpatasvir drug combination
- Velpatasvir
Other Study ID Numbers
- ACTG A5360
- UM1AI068636 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Diseases
-
King's College Hospital NHS TrustSamsung MedisonRecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With FibrosisUnited Kingdom
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver FailureIndia
-
Beijing Friendship HospitalUnknownNonalcoholic Fatty Liver Disease | Liver Steatosis | Liver FibrosisChina
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Medical College of WisconsinRecruiting
-
HaEmek Medical Center, IsraelTerminatedPatients With Fatty Liver DiseaseIsrael
-
Johannes Gutenberg University MainzUniversity of JenaCompletedNon-alcoholic Fatty Liver Disease | Fatty Liver, NonalcoholicGermany
-
The Cleveland ClinicCompleted
-
Hadassah Medical OrganizationUnknown
Clinical Trials on Sofosbuvir/Velpatasvir (SOF/VEL)
-
Johns Hopkins UniversityCompletedHIV | Liver Disease | HCV CoinfectionUnited States
-
Kirby InstituteCompletedHepatitis CAustralia, United States, United Kingdom, New Zealand, Switzerland, Canada, Germany, Netherlands
-
Gilead SciencesTerminatedHepatitis C Virus InfectionUnited States, United Kingdom, Australia, Germany, Italy, New Zealand, Belgium, Poland, Russian Federation
-
The Christ HospitalGilead SciencesCompletedHepatitis C | Pregnancy Complications | Vertical Disease TransmissionUnited States
-
University of Maryland, BaltimoreGilead Sciences; Unity Health Care, Inc.CompletedChronic Hepatitis CUnited States
-
Gilead SciencesCompletedChronic Hepatitis CIsrael, United Kingdom, Australia, Spain, Canada, New Zealand
-
Gilead SciencesCompleted
-
Gilead SciencesCompletedHepatitis C Virus InfectionUnited States, Belgium, Italy, United Kingdom
-
Gilead SciencesCompletedHepatitis C Virus InfectionIndia
-
Gilead SciencesCompletedHepatitis C Virus InfectionUnited States, Puerto Rico